EU Flu Day Launched Today by MEP Dolors Montserrat With Vaccines Europe’s Support
The first annual EU Flu Day is being launched today, 14 October 2020. The campaign seeks to highlight the importance of seasonal flu vaccination, particularly during the ongoing COVID-19 pandemic, and to address challenges for sustainable increase of flu vaccine coverage rates in Europe as a critical public health measure for healthcare systems sustainability.
It is a call to action for European citizens – particularly healthcare workers and at-risk groups – to make them aware of the need to be vaccinated against flu, in order to protect themselves, those around them as well as alleviating the stress on national health care systems.
The campaign is being spearheaded by Dolors Montserrat, a leading Member of the European Parliament (EPP, Spain) and Co-Chair of the Health Working Group. Montserrat is also a former Minister of Health in Spain. The campaign is being organised with the support of Vaccines Europe.
There are several activities being planned for EU Flu Day, including:
- #EUFluDay online campaign: EU Flu Day is an opportunity for policymakers and citizens alike to set an example. Everyone is encouraged to share a message about the importance of getting the flu vaccine on social media, using the hashtag #EUFluDay. EU policy makers have already begun posting messages of support (e.g. here, here, here), and several more are expected over the course of the day.
- EU Flu Day launch webinar: MEP Montserrat is holding a webinar to mark the launch of EU Flu Day, bringing together participants from the European Commission, World Health Organisation, European Parliament, healthcare professionals and the vaccines industry. It is titled “Flu vaccination as a public health measure during COVID-19” and is taking place from 14:00-16:00 CET on 14 October 2020. Speakers will share their views on optimal approaches to increase flu vaccine uptake during COVID-19. This will include how to overcome barriers with the uptake of seasonal flu vaccines, and how to ensure early supply forecast planning, given the long lead times for vaccine production. One key proposal is to extended window for flu vaccination, in order to meet the increased demand caused by a pandemic.
“We are calling on Europeans citizens, particularly health workers and at-risk groups, to get their seasonal flu vaccination, in order to protect themselves and others, and to avoid overwhelming national healthcare systems” said MEP Montserrat. “We want to do all we can to drive action to safeguard public health from seasonal influenza, especially in a COVID-19 setting. That’s why I am calling on EU policymakers to lead by example on 14 October – and throughout the entire season. With an annual EU Flu Day, we have an opportunity to improve flu vaccine uptake rates across the EU for future seasons. Only by taking steps like this can we safeguard public health in the face of a truly unprecedented crisis.”
The importance of flu vaccination during COVID-19
Seasonal flu vaccines are an essential part of the annual public health toolkit. It is estimated that there are up to 50 million cases of seasonal flu in Europe each year, causing up to 70,000 deaths. Seasonal flu also puts a large strain on healthcare systems, for example through hospitalisations. With the dual threat of seasonal flu and COVID-19, uptake of flu vaccines will be even more vital for public health during the 2020/2021 season to prevent the overwhelming of healthcare systems.
The WHO recommends that countries should aim for 75% flu vaccine coverage rate among at-risk groups. Yet no EU country currently meets this target. In fact, the latest available data shows an average uptake level of only 41% of those aged 65 and over, with the lowest score being only 7.7%, while some Member States are above 60%.
The COVID-19 pandemic has increased public awareness of the need for each person to take steps that protect the wider community – particularly those in at-risk groups. Seasonal flu vaccines are one of the most effective ways people can protect themselves, others and healthcare systems, particularly in a COVID-19 pandemic setting. Depending on local recommendations, flu vaccination might be prioritised to at-risk groups at the start of vaccination season, however it is important to note that people - both in and outside scope of risk groups - should consider vaccination even until January and beyond as peak phase of flu can fall to February or March.
Magdalena R. De Azero, Executive Director of Vaccines Europe, said: “The vaccine industry is currently working around the clock to develop, manufacture and supply COVID-19 vaccines. While these efforts continue, manufacturers have also managed to marginally increase their flu vaccine production to cope with increased demand. These efforts should be supported with effective national flu vaccination campaigns to ensure optimal access and uptake.” She added that “flu is an annual public health threat with or without the concurrent pandemic. Therefore, EU Flu Day needs to be a springboard for action. We need to translate ideas into reality – like expanding access to flu vaccines in new healthcare settings like pharmacies, and implementing targeted vaccination campaigns to meet demands of seasonal flu vaccination administration in a COVID-19 setting. Policymakers at both EU and national level have an essential role to play in achieving this – both this year and beyond.”
Vaccines Europe is a specialised group of the European Federation of Pharmaceutical Industries and Associations (EFPIA) that represents major innovative research-based vaccine companies as well as small and medium-sized enterprises operating in Europe which account for a large share of human vaccines used worldwide.
Magdalena R. De Azero
Executive Director, Vaccines Europe
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pacific Drilling Commences Voluntary Chapter 11 Proceedings; Restructuring Support Agreement to Eliminate All $1.1 Billion of Bond Debt; World-wide Operations Expected to Continue as Usual31.10.2020 00:52:00 CET | Press release
Pacific Drilling S.A. (NYSE: PACD) announced today that it and certain of its domestic and international subsidiaries have filed voluntary petitions for relief under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas and have entered into a restructuring support agreement with an ad hoc group of the largest holders of its outstanding bond debt. This consensual financial restructuring transaction will eliminate the Company’s approximately $1.1 billion in principal amount of outstanding bond debt through the cancellation and exchange of debt for new equity in the reorganized Company. The Company also announced today that it has repaid its $50 million first lien superpriority revolving credit agreement with Angelo, Gordon Energy Servicer, LLC, as administrative agent and the lenders party thereto. With approximately $120 million of cash and cash equivalents as of October 30, 2020, and seven of the most advanced high-spe
Homestead Capital Closes Fund III at Target, Surpasses $1 Billion in Cumulative AUM31.10.2020 00:07:00 CET | Press release
Homestead Capital USA LLC (“Homestead”), a private equity firm investing in farmland in the United States, has held a final close of its third fund, Homestead Capital USA Farmland Fund III, L.P. (“Fund III”), with $596 million in capital commitments. With these additional commitments, the firm has surpassed $1 Billion in AUM across its three funds. “We are grateful for the support and opportunity to invest on behalf of our broad range of returning and new investors,” said Dan Little, Co-Founder and Co-CEO of Homestead. “We are humbled by our limited partners’ confidence in us as investors. Fund III represents an endorsement of our ability to drive positive investment outcomes and act as long-term stewards of our limited partners’ capital.” “The United States farmland market continues to undergo a transition that presents many attractive investment opportunities,” said Gabe Santos, also a Co-Founder and Co-CEO of Homestead. “Our strategy is uniquely suited to create value by utilizing o
Bennett Goodman and Avi Kalichstein Launch Hunter Point Capital to Invest in Alternative Investment Managers30.10.2020 19:03:00 CET | Press release
Bennett Goodman and Avi Kalichstein today announced the formation of Hunter Point Capital LP (“HPC”), an independent investment firm seeking minority stakes in middle-market alternative asset managers. As part of the launch, HPC has formed a strategic partnership with a group of leading global investment entities associated with Jacob Rothschild. "I am thrilled to initiate this next phase of my career with such an exceptional team. Our HPC partnership seeks to leverage our collective expertise as investors and business builders to cultivate the next generation of outstanding investment franchises,” said Goodman. “Our goal is to help general partners achieve their long-term business objectives faster and with more certainty.” “At our core, Hunter Point Capital is focused on investment excellence. We seek managers with proven track records, who will benefit from a strategic, impact-oriented partner,” said Kalichstein. “There is an expanding universe of high-performing investment manageme
Code:n@xt: PROCAD to Lift the Veil on a New PLM Generation30.10.2020 17:31:00 CET | Press release
On November 11, 2020, PRO.FILE next, the next product generation by PROCAD will be officially launched. At 11:00 AM EST, 10:00 AM CET, the groundbreaking, cloud-enabled platform for the digital transformation of business processes will be presented to the public for the first time at Code:n@xt, a must-attend event for anyone interested in digital transformation, information and product lifecycle management. PROCAD's managing directors, strategists, business developers, and developers will come together for Code:n@xt to present PRO.FILE next – whose code will change the world of PLM software. The online event will feature breakout sessions and a live demo of the new system, take a look at today's market demands and digital transformation trends, and give attendees the opportunity to chat with the company's experts. Where does digital transformation start? Where does a PLM platform as a Product Data Backbone fit into it? How do you build an information twin as a digital replica of a piec
INX Applies for Listing on the Canadian Securities Exchange (CSE)30.10.2020 14:00:00 CET | Press release
INX Limited (“INX”) today announced its application for listing of its digital security, the INX Token, on the Canadian Securities Exchange (“CSE”). The listing application is subject to the approval of the CSE. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201030005313/en/ Shy Datika, Co-Founder and President at INX (Photo: Business Wire) INX recently launched the first SEC-registered digital security IPO for both retail and institutional investors. INX intends to use the net proceeds from the IPO for a launch of a regulated trading platform for digital assets and provide novel trading and capital raising financial instruments to enterprises in collaboration with traditional exchanges worldwide. The CSE is a proponent of exchange-listed digital securities and continues to work towards additional services in connection with the post-trade processes for these securities. Richard Carleton, CEO of the CSE has stated that “The
Veracyte Announces New Data Published in Journal of Clinical Oncology Suggest the Prosigna Breast Cancer Test’s Genomic Underpinning Drives Prognostic Performance30.10.2020 13:15:00 CET | Press release
Veracyte, Inc., (Nasdaq: VCYT) announced today that findings from the first study evaluating the molecular drivers underlying multiple prognostic genomic breast cancer tests were published in the Journal of Clinical Oncology (JCO). Results suggest that the genomic underpinnings of Veracyte’s Prosigna® Breast Cancer Gene Signature Assay, particularly the test’s relative weighting of genes predicting tumor proliferation, may explain the classifier’s previously demonstrated, higher likelihood of predicting long-term risk of recurrence among certain breast cancer patients, compared to other breast cancer tests. The study compared the commercial forms of four breast cancer recurrence-risk tests: the PAM50-based Prosigna Risk of Recurrence (ROR), the Oncotype DX Risk Score (RS), EndoPredict (EP) and Breast Cancer Index (BCI). It expands upon a previous evaluation of these same tests using an identical dataset, which compared their ability to accurately predict 10-year distant disease recurre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom